EC Neurology

Metabolic syndrome (MetS) refers to the group of several interconnected risk factors that collectively double the risk of cardiovascular disease. Epilepsy is linked to MetS across all age groups, though its prevalence differs across various studies. This can be understood from the perspective of seizure-related metabolic abnormalities, long-term antiepileptic drugs (AEDs) use, and a more sedentary lifestyle due to epilepsy. The factors that are considered in developing MetS for patients with epilepsy (PWE) are age, residence, level of physical activity, food intake status, epilepsy subtype, epilepsy duration, current (AEDs) use, drug responsiveness status, body-mass index (BMI), total cholesterol and LDL-cholesterol levels. A deeper understanding of the epilepsy-AED-MetS connection and the exploration of lifestyle interventions hold the promise of significantly improving the overall health and well-being of PWE. Clinicians managing PWE should closely monitor various risk factors for developing MetS and consider them when selecting AED treatment.

 Keywords: Metabolic Syndrome; Epilepsy; Dyslipidemia; Antiepileptic Drugs

1. Huang PL. “A comprehensive definition for metabolic syndrome”. Disease Models and Mechanisms 5-6 (2009): 231-237.
2. Dobrowolski P., et al. “Metabolic syndrome - a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons”. Archives of Medical Science 5 (2022): 1133-1156.
3. Nair SS., et al. “Metabolic syndrome in young adults with epilepsy”. Seizure 37 (2016): 61-64.
4. Beyene Kassaw A., et al. “Metabolic syndrome and its associated factors among epileptic patients at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia a hospital-based comparative cross-sectional study”. PLoS One12 (2022): e0279580.
5. Ndayambaje FX., et al. “Prevalence and Risk Factors for the Metabolic Syndrome among Patients with Epilepsy Attending a Neuropsychiatric Hospital in Kigali, Rwanda”. International Journal of Advanced Scientific Research and Management4 (2021): 1-8.
6. Shan Y., et al. “Regulatory Basis of Adipokines Leptin and Adiponectin in Epilepsy: from Signaling Pathways to Glucose Metabolism”. Neurochemical Research 7 (2023): 2017-2028.
7. Hamed SA. “Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions”. Epilepsy Research 1 (2007): 1-9.
8. Qiao L., et al. “Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid”. Endocrinology2 (2006): 865-874.
9. Sidhu HS., et al. “Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study”. Seizure 48 (2017): 15-21.
10. Aly RH., et al. “Insulin resistance in patients on valproic acid: relation to adiponectin”. Acta Neurologica Scandinavica 3 (2015): 169-175.
11. Tiwari A and Balasundaram P. “Public Health Considerations Regarding Obesity”. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2024).
12. Carrizosa-Moog J., et al. “Epilepsy, Physical Activity and Sports: A Narrative Review”. Canadian Journal of Neurological Sciences 6 (2018): 624-632.
13. Hinnell C., et al. “Health status and health-related behaviors in epilepsy compared to other chronic conditions--a national population-based study”. Epilepsia5 (2010): 853-861.
14. Jalava M and Sillanpää M. “Physical activity, health-related fitness, and health experience in adults with childhood-onset epilepsy: a controlled study”. Epilepsia4 (1997): 424-429.
15. Cui W., et al. “Health behaviors among people with epilepsy--results from the 2010 National Health Interview Survey”. Epilepsy and Behavior 44 (2015): 121-126.
16. Nakken KO. “Physical exercise in outpatients with epilepsy”. Epilepsia5 (1999): 643-651.
17. Szałwińska K., et al. “Dietary and lifestyle behavior in adults with epilepsy needs improvement: a case-control study from northeastern Poland”. Nutrition Journal 1 (2021): 62.
18. Wong J and Wirrell E. “Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy”. Epilepsia3 (2006): 631-639.
19. Capovilla G., et al. “Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy”. Epilepsia1 (2016): 6-12.
20. Vīksna Z and Ligere R. "Eating Habits of Children and Adolescents with Epilepsy in Latvia". Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences 4-5 (2013): 350-356.
21. Bahagat KA., et al. “Cociente omega-6/omega-3 y cogniciónenniños con epilepsia [Omega-6/omega-3 ratio and cognition in children with epilepsy]”. Anales de Pediatría (English Edition) 2 (2019): 88-95.
22. de Azevedo Fernandez R., et al. “Anthropometric profile and nutritional intake in patients with epilepsy”. Nutrición Hospitalaria 2 (2015): 817-822.
23. Elliott JO., et al. “Health status and behavioral risk factors among persons with epilepsy in Ohio based on the 2006 Behavioral Risk Factor Surveillance System”. Epilepsy and Behavior 3 (2008): 434-444.
24. Elliott JO., et al. “Exercise, diet, health behaviors and risk factors among persons with epilepsy based on the California Health Interview Survey 2005”. Epilepsy and Behavior 2 (2008): 307-315.
25. Doonan RJ., et al. “The effect of smoking on arterial stiffness”. Hypertension Research 5 (2010): 398-410.
26. Zuberi NA., et al. “Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment”. Neurosciences (Riyadh)2 (2017): 114-118.
27. Nisha Y., et al. “Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid”. Seizure 60 (2018): 57-60.
28. Güler S. “Development of Insulin Resistance in Patients with Epilepsy During Valproate and Carbamazepine Monotherapy”. Journal of the Turkish Epilepsy Society (2016).
29. Sonmez FM., et al. “The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy”. Seizure10 (2013): 856-861.
30. Sepahi S., et al. “Effect of valproic acid on metabolic status and endocrine system in pediatric patients with epilepsy: systematic literature review”. Reviews in Clinical Medicine1 (2017): 7-13.
31. George LJ., et al. “Insulin Resistance in children on Sodium Valproate - A hospital based cross-sectional study in Indian children”. Tropical Doctor 1 (2023): 91-96.
32. Sidhu HS., et al. “Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study”. Epilepsy Research 139 (2018): 20-27.
33. Tomson T., et al. “Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry”. Lancet Neurology6 (2018): 530-538.
34. Mintzer S., et al. “Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein”. Annals of Neurology 4 (2009): 448-456.
35. Huang CR., et al. “Zonisamide Therapy Reduces Metabolic Consequences and Diminishes Nonalcoholic Fatty Liver Disease in Patients with Epilepsy”. Journal of Clinical Medicine 15 (2021): 3380.